CNS Blood Cancer Lymphoma FDA Trial

As mentioned before...I think the Dana Farber selection of their drug Paxalasib for a Phase 2 Clinical Trial was the most significant ASX release for the whole of last year.

Given at least, that the April news of positive GBM data was flagged by the company. The company makes reference to their drug in GBM, DIPG and Brain Mets. How much do we hear about Paxalisib in blood cancer ? How many times has PCNSL been mentioned here ?

The announcement in Sept of this trial was grossly undersold by the company. I hope this link opens at the bottom to help to explain this disease and back up what I have said.

The link, perfectly confirms that PCNSL is blood cancer lymphoma. (shows I have not used out of context wording here). Some selective cut and paste anyway, if this PDF link from Aust, does not open.The link perfectily explains about blood cancer....... and the story confirms I think - this trial in blood cancer sits nicely with their other efforts in GBM, DIPG and CNS Mets.Some of biggest selling drugs in the world already have been trialled in PCNSL.....but Dana Farber have chosen Pax in monotheropy. It is just outstanding - beyond belief for such a tiny cap.

There is nothing hidden or left out, or over exaggerated here. Dana Farber undertake exhaustive best in the world studies on their cancer research and treatment.....for the SP on the day of this announcement to be flat on nothing volume - really makes long term investor/trader types like myself - fell sick. Blood cancer drugs - such as those listed below are worth tens, hundreds of billions of dollars - DF went with Paxalisib and the SP did not move. Wake up investors - can't you see where the problem lies ?

For the next person who says "Oh the SP will eventually move higher" - well that being the case - why are you putting effort into posting positive stuff now ? why do we have a chatline ? ......NO investors desire a return for their risk at some half decent semblance of value (avoiding hopelessly undervalued CR and a chance for a reasonable deal, off a decent market cap, are other reasons)

"TREATMENTS UNDER INVESTIGATIONMany new individual and combination medicines are currently being tested in clinical trials around the world for both newly diagnosed and relapsed/refractory

• Ibrutinib (ImbruvicaR) • Lenalidomide (RevlimidR) • Nivolumab (OpdivoR) • Obinutuzumab (GazyvaR) • Pembrolizumab (KeytrudaR)

Primary Central Nervous System Lymphoma (PCNSL) is an aggressive form of lymphoma in which lymphoma cells form in the brain and/or spinal cord. In more than 90% of cases it is a B-cell lymphoma that may develop in the brain, spinal cord, eye or leptomeninges .........

"https://lymphoma.org.au/wp-content/uploads/2020/07/LYA084_PCNSL_FactSheet_web.pdf